🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Syngene International Limited SYNGENE NIFTY_SMALLNSEPHARMA

Healthcare · Diagnostics & Research · India
https://www.syngeneintl.com
Company Profile ↓
₹421.55
-33.35% 1Y
Mkt Cap₹16,985.91 Cr
P/E34.16
P/B3.49
Div. Yield0.30%
52W High₹720.01
52W Low₹388.80
Book Value₹120.09
EPS (TTM)₹12.34

Company Overview

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Why Investors Should Care

Reasonable Valuation

Trades at a P/E of 34.2, below the sector median of 40.0.

Healthy Margins

Operating margin of 15.4% supports profitability.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.09.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹3,610.70 Cr (+2.8% YoY); net profit ₹316.70 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +2.8%, earnings -36.2%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.4%, profit CAGR -12.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.44%
1 Year:2.79%

Compounded Profit Growth

5 Years:-11.98%
1 Year:-36.17%

Stock Price Performance

1 Year:-33.35%
6 Months:-33.30%
3 Months:-3.17%
1 Month:-6.70%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 10% of range
₹388.80 ₹720.01
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)41.66 · Neutral
Price Performance
1M-6.70%
3M-3.17%
6M-33.30%
1Y-33.35%
Valuation vs Sector

P/E of 34.16 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Generates positive free cash flow.

CONS

  • Earnings shrank at -12.0% CAGR over 5 years.
  • Trading 41.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
34.16
Industry PE
39.97
Forward P/E
33.62
PEG Ratio
-
Book Value
₹120.09
Price to Book
3.49
P/S
4.52
EV/EBITDA
17.28
Dividend Yield
0.30%

Growth (CAGR)

Revenue 5Y
5.44%
Profit 5Y
-11.98%
Revenue (YoY)
2.79%
Earnings (YoY)
-36.17%

Profitability & Returns

ROCE
8.28%
ROE
6.54%
ROA
4.49%
Profit Margin
8.77%
Op Margin
15.43%
Gross Margin
74.56%
EPS (Latest Qtr)
₹3.67
EPS (TTM)
₹12.34

Balance Sheet & Liquidity

Debt/Equity
0.09
Quick Ratio
1.29
Current Ratio
1.38
Debt
₹458.40 Cr
Total Assets
₹7,054.70 Cr
Current Assets
₹2,142.80 Cr
Working Capital
₹590.50 Cr

Ownership

Promoter Holding
52.80%
Chg in Prom Hold
-0.00%
FII / Inst Holding
38.16%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
₹16,985.91 Cr
Total Revenue (TTM)
₹3,610.70 Cr
EBITDA
₹908.60 Cr
Free Cash Flow
₹547.00 Cr
Operating Cash Flow
₹915.20 Cr
Shares Outstanding
₹40.29 Cr
Gross Margin
74.56%
Payout Ratio
15.88%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SYNGENE Syngene International Limited NIFTY_SMALLNSEPHARMA 421.55 34.16 ₹16,985.91 Cr 0.30% 8.28% 6.54% 5.44% -11.98%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 994.00 Cr808.00 Cr910.00 Cr854.00 Cr917.00 Cr790.00 Cr891.00 Cr943.70 Cr1,018.00 Cr874.50 Cr911.00 Cr917.10 Cr1,036.50 Cr
Cost of Revenue -------237.40 Cr235.00 Cr217.60 Cr-229.40 Cr233.10 Cr
Gross Profit -------706.30 Cr783.00 Cr656.90 Cr-687.70 Cr803.40 Cr
Operating Expenses 680.00 Cr596.00 Cr656.00 Cr622.00 Cr600.00 Cr620.00 Cr646.00 Cr533.10 Cr540.90 Cr556.90 Cr711.00 Cr569.00 Cr590.40 Cr
Operating Income 218.00 Cr110.00 Cr149.00 Cr124.00 Cr206.00 Cr63.00 Cr134.00 Cr173.20 Cr242.10 Cr100.00 Cr84.00 Cr118.70 Cr213.00 Cr
EBITDA 314.00 Cr212.00 Cr254.00 Cr232.00 Cr317.00 Cr170.00 Cr245.00 Cr301.90 Cr362.50 Cr224.10 Cr200.00 Cr154.00 Cr319.60 Cr
Interest Expense 10.00 Cr10.00 Cr13.00 Cr11.00 Cr13.00 Cr12.00 Cr13.00 Cr12.40 Cr15.90 Cr11.60 Cr13.00 Cr11.90 Cr12.10 Cr
Pretax Income 231.00 Cr123.00 Cr151.00 Cr138.00 Cr209.00 Cr101.00 Cr137.00 Cr180.80 Cr240.50 Cr101.30 Cr85.00 Cr28.40 Cr196.00 Cr
Tax Provision 53.13 Cr29.52 Cr34.73 Cr26.22 Cr20.90 Cr25.25 Cr31.51 Cr49.70 Cr57.20 Cr14.60 Cr17.85 Cr13.40 Cr48.10 Cr
Net Income 179.00 Cr93.00 Cr116.00 Cr112.00 Cr189.00 Cr76.00 Cr106.00 Cr131.10 Cr183.30 Cr86.70 Cr67.00 Cr15.00 Cr147.90 Cr
Diluted EPS 4.452.322.902.774.691.882.643.264.562.151.670.373.67

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,423.00 Cr1,826.00 Cr2,012.00 Cr2,184.00 Cr-3,080.20 Cr3,369.50 Cr3,512.80 Cr3,610.70 Cr
Cost of Revenue -----860.20 Cr930.20 Cr942.50 Cr918.60 Cr
Gross Profit -----2,220.00 Cr2,439.30 Cr2,570.30 Cr2,692.10 Cr
Operating Expenses 949.00 Cr1,289.00 Cr1,394.00 Cr1,507.00 Cr-1,601.80 Cr1,792.20 Cr1,956.90 Cr2,134.80 Cr
Operating Income 343.00 Cr373.00 Cr399.00 Cr404.00 Cr-618.20 Cr647.10 Cr613.40 Cr557.30 Cr
EBITDA 474.00 Cr537.00 Cr618.00 Cr678.00 Cr-994.60 Cr1,091.80 Cr1,141.70 Cr908.60 Cr
Interest Expense 23.00 Cr32.00 Cr35.00 Cr28.00 Cr-34.50 Cr45.10 Cr49.20 Cr44.80 Cr
Pretax Income 372.00 Cr415.00 Cr517.00 Cr469.00 Cr-593.60 Cr620.80 Cr659.90 Cr410.90 Cr
Tax Provision 66.96 Cr83.00 Cr103.40 Cr65.66 Cr-129.20 Cr110.80 Cr163.70 Cr94.20 Cr
Net Income 305.00 Cr332.00 Cr412.00 Cr405.00 Cr-464.40 Cr510.00 Cr496.20 Cr316.70 Cr
Diluted EPS 7.648.2910.3010.129.8211.5112.6912.34-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 3,189.00 Cr3,704.00 Cr4,163.00 Cr4,883.00 Cr-5,831.00 Cr6,151.60 Cr6,795.90 Cr7,054.70 Cr
Current Assets -----2,425.30 Cr1,959.00 Cr2,287.30 Cr2,142.80 Cr
Cash & Equivalents -----87.00 Cr85.60 Cr366.90 Cr228.60 Cr
Inventory -----332.80 Cr238.50 Cr155.50 Cr141.30 Cr
Receivables -----529.30 Cr441.60 Cr526.80 Cr508.80 Cr
Total Liabilities -----2,213.00 Cr1,893.90 Cr2,069.00 Cr2,215.70 Cr
Current Liabilities -----1,188.20 Cr1,144.30 Cr1,396.40 Cr1,552.30 Cr
Long Term Debt ----531.50 Cr489.00 Cr100.00 Cr0-
Total Debt 787.00 Cr813.00 Cr773.00 Cr893.00 Cr-815.20 Cr555.20 Cr577.90 Cr458.40 Cr
Total Equity 1,720.00 Cr1,968.00 Cr2,176.00 Cr2,821.00 Cr-3,618.00 Cr4,257.70 Cr4,726.90 Cr4,839.00 Cr
Shares Outstanding -----40.14 Cr40.20 Cr40.25 Cr40.29 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 446.00 Cr630.00 Cr677.00 Cr701.00 Cr-823.50 Cr1,042.10 Cr1,167.60 Cr915.20 Cr
Investing Cash Flow -349.00 Cr-646.00 Cr-424.00 Cr-629.00 Cr--656.40 Cr-495.60 Cr-744.70 Cr-860.40 Cr
Financing Cash Flow -79.00 Cr-72.00 Cr-226.00 Cr58.00 Cr--342.50 Cr-551.40 Cr-141.80 Cr-215.00 Cr
Capital Expenditure -364.00 Cr-583.00 Cr-643.00 Cr-446.00 Cr--518.30 Cr-510.80 Cr-770.10 Cr-368.20 Cr
Free Cash Flow 82.00 Cr47.00 Cr34.00 Cr255.00 Cr-305.20 Cr531.30 Cr397.50 Cr547.00 Cr
Net Change in Cash 18.00 Cr-88.00 Cr28.00 Cr130.00 Cr--175.40 Cr-4.90 Cr281.10 Cr-160.20 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -----72.1%72.4%73.2%74.6%
Operating Margin % 24.1%20.4%19.8%18.5%-20.1%19.2%17.5%15.4%
Net Margin % 21.4%18.2%20.5%18.5%-15.1%15.1%14.1%8.8%
ROE % 17.7%16.9%18.9%14.4%-12.8%12.0%10.5%6.5%
ROCE % -----13.3%12.9%11.4%10.1%

Shareholding Pattern

Insiders
52.80%
Institutions
38.16%
Public Float
80.84%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SYNGENE

Google News ue, 14 Jul 2026

Syngene International accepts General Counsel resignation - scanx.trade

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNN1ZKMXFuejc5NjlzX05Pc2FWcWNPeENVQi1PMGFBbFBZU3VKNk5ZOTg2LUJGaENOZTU4RE1idFg1dGI5cU1JSlNfRk5lci02SUNwemVpb1ZuckRHY1Q5MmpYdHJYSjh1MW5sYnAyRkRGYUY5dXh0ZkdvcG5FNHcyUUR2c3dBS0lXN1Q1R2…

Google News Sun, 21 Jun 2026

Just Three Days Till Syngene International Limited (NSE:SYNGENE) Will Be Trading Ex-Dividend - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxOZVlLbjRHbTFVQ2ZyV2FIZGE4d1pyMml2cFItVS1hQlpsOWRtcEo0VVdPSDgzYmVuSlNYZ0VuNlJBN2hIOFBaMWE5b0RKRGhDVFROV0JqMW80MFB4V1RuamJCOGtGX1B2dGhtNGhZS3o0S3VkYlNjeHhyd2E1UHpTUUhwSGpScEd5dmVrd0…

Google News hu, 02 Apr 2026

Weeks after Otsuka license, Biodexa secures MTX240 trial manufacturing - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQTDBzX2JNQlNGV0tQekVEZDkzZks1OG1XQmhIVE5aWVdPNVhQSHlZTDZGLW4wZVJyNXNrRmtzUjFQX1NoTDNaZUc2WjlTZGNlNWg0UlhLRlNCYnNqQ2tFTUZILUFrNlJMSXNjdmEtMUx6YU9yV04wVFI2dWFoT09henNWVktTZjAzZktKQW…

Google News ue, 23 Jun 2026

Syngene International: Could India’s WuXi moment finally be here? - The Indian Express

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPT3ItR0xJZDEtQnROdmt0M21zQi1Ydm1QTkI2b0hzX3p6QUxQUklxV0hDVnd1cVhlTGdmZkpTdi1QeDBGeUlaOGVFZ3Y4eXB0bjNOUEp4amF3eHhuUk1ZT1Q5eEp3S2ZTbmRlbE02WV9MZDhDdFBueFVXLW1qOUVjdEhCODQ0d0dpTzcwM3…

Google News hu, 30 Apr 2026

Syngene shares zoom 17% even as firm’s Q4 net profit drops 19% YoY. What's driving the surge? - The Economic Times

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxQUDRqdkJzbFlFRTlTZHh3VXc3VTNpOHJfSlV2Vzh1TEh2dTNTeFpRVWRkYUJXUWgxekZYWUV5V1B2bDVtTDRHSllqQXZzRmtheG9DYmJjLXpmenhYclFBOXJzXzBnZzRKRjZIZ255am1OclZ3WXhOelRFRml0Nmo5WWcwNUt1U2VrUVZKb0…

Google News Fri, 03 Jul 2026

SYNGENE Outlook for the Week (July 13, 2026 – July 17, 2026) - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE40dkMxSzRxVzhLLWk0UlVseFZrWlBzMmVDbzBWaXpNOHlLQ0gwNDd0Umk5dmZ6LU42ZmlkRWkxVU52M1dYWEhEMkdDTUI0WkZfTnplX2t5YTVDdDlUTVFOVFN2dUl1YkI0Z1E?oc=5" target="_blank">SYNGENE Outlook for the …

SYNGENE — Frequently Asked Questions

What is the current share price of Syngene International Limited (SYNGENE)?

As of 2026-07-15 09:52 IST, Syngene International Limited (SYNGENE) trades at ₹421.55 on NSE. Its 52-week range is ₹388.80 to ₹720.01.

What is the market capitalisation of SYNGENE?

Syngene International Limited (SYNGENE) has a market capitalisation of ₹16,985.91 Cr on NSE.

What is the P/E ratio of SYNGENE?

SYNGENE trades at a trailing price-to-earnings (P/E) ratio of 34.16. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.49.

Does SYNGENE pay a dividend?

Syngene International Limited (SYNGENE) currently offers a dividend yield of 0.30%.

What is the return on equity (ROE) of SYNGENE?

SYNGENE has a return on equity (ROE) of 6.54%. Its return on capital employed (ROCE) is 8.28%.

Is SYNGENE a good stock to buy?

This page provides a data-driven analysis of Syngene International Limited (SYNGENE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space